nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—FGFR3—cervical cancer	0.589	1	CbGaD
Pazopanib—ABCG2—Topotecan—cervical cancer	0.0967	0.634	CbGbCtD
Pazopanib—ABCB1—Topotecan—cervical cancer	0.0349	0.229	CbGbCtD
Pazopanib—CYP3A4—Topotecan—cervical cancer	0.0209	0.137	CbGbCtD
Pazopanib—Tumour pain—Topotecan—cervical cancer	0.011	0.292	CcSEcCtD
Pazopanib—Mucosal inflammation—Topotecan—cervical cancer	0.00188	0.0497	CcSEcCtD
Pazopanib—Rash erythematous—Topotecan—cervical cancer	0.00136	0.036	CcSEcCtD
Pazopanib—Hyperbilirubinaemia—Topotecan—cervical cancer	0.00114	0.0303	CcSEcCtD
Pazopanib—Blood bilirubin increased—Topotecan—cervical cancer	0.0011	0.0291	CcSEcCtD
Pazopanib—Pulmonary embolism—Topotecan—cervical cancer	0.00104	0.0275	CcSEcCtD
Pazopanib—TAOK1—uterine cervix—cervical cancer	0.00103	0.00887	CbGeAlD
Pazopanib—MAP3K9—female reproductive system—cervical cancer	0.00102	0.00885	CbGeAlD
Pazopanib—ITK—endometrium—cervical cancer	0.00102	0.00881	CbGeAlD
Pazopanib—ITK—mammalian vulva—cervical cancer	0.000987	0.00852	CbGeAlD
Pazopanib—TAOK1—decidua—cervical cancer	0.000978	0.00845	CbGeAlD
Pazopanib—SH2B3—uterine cervix—cervical cancer	0.000967	0.00835	CbGeAlD
Pazopanib—TAOK1—renal system—cervical cancer	0.00096	0.0083	CbGeAlD
Pazopanib—MAP3K9—female gonad—cervical cancer	0.000932	0.00805	CbGeAlD
Pazopanib—TAOK1—endometrium—cervical cancer	0.000929	0.00802	CbGeAlD
Pazopanib—MAP3K9—vagina—cervical cancer	0.000927	0.008	CbGeAlD
Pazopanib—SH2B3—decidua—cervical cancer	0.000921	0.00795	CbGeAlD
Pazopanib—TAOK1—mammalian vulva—cervical cancer	0.000898	0.00776	CbGeAlD
Pazopanib—SH2B3—endometrium—cervical cancer	0.000874	0.00755	CbGeAlD
Pazopanib—TAOK1—uterus—cervical cancer	0.000856	0.00739	CbGeAlD
Pazopanib—KIT—exocrine gland—cervical cancer	0.000853	0.00736	CbGeAlD
Pazopanib—SH2B3—mammalian vulva—cervical cancer	0.000846	0.0073	CbGeAlD
Pazopanib—FGFR3—epithelium—cervical cancer	0.000816	0.00705	CbGeAlD
Pazopanib—RIOK2—uterine cervix—cervical cancer	0.000809	0.00699	CbGeAlD
Pazopanib—FGFR3—uterine cervix—cervical cancer	0.000809	0.00699	CbGeAlD
Pazopanib—BMPR1B—epithelium—cervical cancer	0.000808	0.00698	CbGeAlD
Pazopanib—SH2B3—uterus—cervical cancer	0.000806	0.00696	CbGeAlD
Pazopanib—Lethargy—Topotecan—cervical cancer	0.000771	0.0204	CcSEcCtD
Pazopanib—RIOK2—decidua—cervical cancer	0.000771	0.00666	CbGeAlD
Pazopanib—TAOK1—female reproductive system—cervical cancer	0.000769	0.00664	CbGeAlD
Pazopanib—ITK—vagina—cervical cancer	0.000764	0.0066	CbGeAlD
Pazopanib—FGFR3—renal system—cervical cancer	0.000757	0.00654	CbGeAlD
Pazopanib—RIOK2—endometrium—cervical cancer	0.000732	0.00632	CbGeAlD
Pazopanib—STK36—uterine cervix—cervical cancer	0.000727	0.00628	CbGeAlD
Pazopanib—PI4KB—uterine cervix—cervical cancer	0.000716	0.00618	CbGeAlD
Pazopanib—AURKC—female reproductive system—cervical cancer	0.000713	0.00616	CbGeAlD
Pazopanib—RIOK2—mammalian vulva—cervical cancer	0.000708	0.00611	CbGeAlD
Pazopanib—FGFR3—mammalian vulva—cervical cancer	0.000708	0.00611	CbGeAlD
Pazopanib—LIMK2—uterine cervix—cervical cancer	0.000703	0.00607	CbGeAlD
Pazopanib—TAOK1—female gonad—cervical cancer	0.0007	0.00605	CbGeAlD
Pazopanib—TAOK1—vagina—cervical cancer	0.000696	0.00601	CbGeAlD
Pazopanib—STK36—decidua—cervical cancer	0.000692	0.00598	CbGeAlD
Pazopanib—PI4KB—decidua—cervical cancer	0.000682	0.00589	CbGeAlD
Pazopanib—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.000681	0.018	CcSEcCtD
Pazopanib—PI4KB—renal system—cervical cancer	0.000669	0.00578	CbGeAlD
Pazopanib—LIMK2—decidua—cervical cancer	0.000669	0.00578	CbGeAlD
Pazopanib—BMPR1B—uterus—cervical cancer	0.000668	0.00577	CbGeAlD
Pazopanib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.000667	0.0176	CcSEcCtD
Pazopanib—SH2B3—female gonad—cervical cancer	0.000659	0.00569	CbGeAlD
Pazopanib—STK36—endometrium—cervical cancer	0.000657	0.00568	CbGeAlD
Pazopanib—SH2B3—vagina—cervical cancer	0.000655	0.00566	CbGeAlD
Pazopanib—PLK4—female reproductive system—cervical cancer	0.000652	0.00563	CbGeAlD
Pazopanib—PI4KB—endometrium—cervical cancer	0.000647	0.00559	CbGeAlD
Pazopanib—FLT4—epithelium—cervical cancer	0.000637	0.0055	CbGeAlD
Pazopanib—STK36—mammalian vulva—cervical cancer	0.000636	0.00549	CbGeAlD
Pazopanib—LIMK2—endometrium—cervical cancer	0.000635	0.00549	CbGeAlD
Pazopanib—PIP4K2C—uterine cervix—cervical cancer	0.000628	0.00542	CbGeAlD
Pazopanib—PI4KB—mammalian vulva—cervical cancer	0.000626	0.00541	CbGeAlD
Pazopanib—FGFR1—uterine cervix—cervical cancer	0.000623	0.00538	CbGeAlD
Pazopanib—STK16—female reproductive system—cervical cancer	0.000616	0.00532	CbGeAlD
Pazopanib—LIMK2—mammalian vulva—cervical cancer	0.000615	0.00531	CbGeAlD
Pazopanib—Neutropenia—Topotecan—cervical cancer	0.000611	0.0162	CcSEcCtD
Pazopanib—FGFR3—female reproductive system—cervical cancer	0.000606	0.00524	CbGeAlD
Pazopanib—RIOK2—female reproductive system—cervical cancer	0.000606	0.00524	CbGeAlD
Pazopanib—FLT4—decidua—cervical cancer	0.000602	0.0052	CbGeAlD
Pazopanib—MAP3K19—female reproductive system—cervical cancer	0.0006	0.00518	CbGeAlD
Pazopanib—BMPR1B—female reproductive system—cervical cancer	0.0006	0.00518	CbGeAlD
Pazopanib—MAP3K9—lymph node—cervical cancer	0.000599	0.00518	CbGeAlD
Pazopanib—PIP4K2C—decidua—cervical cancer	0.000598	0.00517	CbGeAlD
Pazopanib—PI4KB—uterus—cervical cancer	0.000596	0.00515	CbGeAlD
Pazopanib—MAP3K2—uterine cervix—cervical cancer	0.000595	0.00514	CbGeAlD
Pazopanib—FGFR1—decidua—cervical cancer	0.000593	0.00513	CbGeAlD
Pazopanib—LIMK2—uterus—cervical cancer	0.000586	0.00506	CbGeAlD
Pazopanib—Infestation—Topotecan—cervical cancer	0.000582	0.0154	CcSEcCtD
Pazopanib—Infestation NOS—Topotecan—cervical cancer	0.000582	0.0154	CcSEcCtD
Pazopanib—PIP4K2C—endometrium—cervical cancer	0.000568	0.00491	CbGeAlD
Pazopanib—Stomatitis—Topotecan—cervical cancer	0.000568	0.015	CcSEcCtD
Pazopanib—FGF1—epithelium—cervical cancer	0.000566	0.00489	CbGeAlD
Pazopanib—STK16—female gonad—cervical cancer	0.00056	0.00484	CbGeAlD
Pazopanib—LCK—uterine cervix—cervical cancer	0.000557	0.00481	CbGeAlD
Pazopanib—STK16—vagina—cervical cancer	0.000557	0.00481	CbGeAlD
Pazopanib—RIOK2—female gonad—cervical cancer	0.000552	0.00476	CbGeAlD
Pazopanib—Hepatobiliary disease—Topotecan—cervical cancer	0.000551	0.0146	CcSEcCtD
Pazopanib—PIP4K2C—mammalian vulva—cervical cancer	0.000549	0.00474	CbGeAlD
Pazopanib—Epistaxis—Topotecan—cervical cancer	0.000549	0.0145	CcSEcCtD
Pazopanib—RIOK2—vagina—cervical cancer	0.000548	0.00474	CbGeAlD
Pazopanib—BMPR1B—female gonad—cervical cancer	0.000546	0.00472	CbGeAlD
Pazopanib—FGFR1—mammalian vulva—cervical cancer	0.000545	0.00471	CbGeAlD
Pazopanib—STK36—female reproductive system—cervical cancer	0.000544	0.0047	CbGeAlD
Pazopanib—PI4KB—female reproductive system—cervical cancer	0.000536	0.00463	CbGeAlD
Pazopanib—FGFR2—epithelium—cervical cancer	0.000534	0.00461	CbGeAlD
Pazopanib—LCK—decidua—cervical cancer	0.000531	0.00459	CbGeAlD
Pazopanib—FGFR2—uterine cervix—cervical cancer	0.00053	0.00457	CbGeAlD
Pazopanib—LIMK2—female reproductive system—cervical cancer	0.000526	0.00455	CbGeAlD
Pazopanib—Haemoglobin—Topotecan—cervical cancer	0.000525	0.0139	CcSEcCtD
Pazopanib—FGF1—renal system—cervical cancer	0.000525	0.00453	CbGeAlD
Pazopanib—Haemorrhage—Topotecan—cervical cancer	0.000523	0.0138	CcSEcCtD
Pazopanib—Hypoaesthesia—Topotecan—cervical cancer	0.00052	0.0138	CcSEcCtD
Pazopanib—FGFR1—uterus—cervical cancer	0.000519	0.00448	CbGeAlD
Pazopanib—MAP3K2—uterus—cervical cancer	0.000496	0.00428	CbGeAlD
Pazopanib—STK36—female gonad—cervical cancer	0.000495	0.00428	CbGeAlD
Pazopanib—FGFR2—renal system—cervical cancer	0.000495	0.00428	CbGeAlD
Pazopanib—FLT1—epithelium—cervical cancer	0.000495	0.00428	CbGeAlD
Pazopanib—ITK—lymph node—cervical cancer	0.000494	0.00427	CbGeAlD
Pazopanib—STK36—vagina—cervical cancer	0.000492	0.00425	CbGeAlD
Pazopanib—FLT1—uterine cervix—cervical cancer	0.000491	0.00424	CbGeAlD
Pazopanib—PI4KB—female gonad—cervical cancer	0.000488	0.00421	CbGeAlD
Pazopanib—LCK—mammalian vulva—cervical cancer	0.000488	0.00421	CbGeAlD
Pazopanib—EPHB6—uterine cervix—cervical cancer	0.000485	0.00419	CbGeAlD
Pazopanib—PI4KB—vagina—cervical cancer	0.000485	0.00419	CbGeAlD
Pazopanib—LIMK2—female gonad—cervical cancer	0.000479	0.00414	CbGeAlD
Pazopanib—LIMK2—vagina—cervical cancer	0.000476	0.00411	CbGeAlD
Pazopanib—Angiopathy—Topotecan—cervical cancer	0.000474	0.0125	CcSEcCtD
Pazopanib—FLT4—female reproductive system—cervical cancer	0.000473	0.00409	CbGeAlD
Pazopanib—Mediastinal disorder—Topotecan—cervical cancer	0.000471	0.0125	CcSEcCtD
Pazopanib—PIP4K2C—female reproductive system—cervical cancer	0.00047	0.00406	CbGeAlD
Pazopanib—Chills—Topotecan—cervical cancer	0.000469	0.0124	CcSEcCtD
Pazopanib—FLT1—decidua—cervical cancer	0.000468	0.00404	CbGeAlD
Pazopanib—STK10—uterine cervix—cervical cancer	0.000465	0.00401	CbGeAlD
Pazopanib—LCK—uterus—cervical cancer	0.000465	0.00401	CbGeAlD
Pazopanib—TAOK3—uterine cervix—cervical cancer	0.000463	0.004	CbGeAlD
Pazopanib—EPHB6—decidua—cervical cancer	0.000462	0.00399	CbGeAlD
Pazopanib—Alopecia—Topotecan—cervical cancer	0.000462	0.0122	CcSEcCtD
Pazopanib—FLT1—renal system—cervical cancer	0.000459	0.00397	CbGeAlD
Pazopanib—Malnutrition—Topotecan—cervical cancer	0.000455	0.012	CcSEcCtD
Pazopanib—TAOK1—lymph node—cervical cancer	0.00045	0.00389	CbGeAlD
Pazopanib—MAP3K2—female reproductive system—cervical cancer	0.000446	0.00385	CbGeAlD
Pazopanib—FLT1—endometrium—cervical cancer	0.000444	0.00383	CbGeAlD
Pazopanib—STK10—decidua—cervical cancer	0.000443	0.00382	CbGeAlD
Pazopanib—FGFR2—uterus—cervical cancer	0.000441	0.00381	CbGeAlD
Pazopanib—TAOK3—decidua—cervical cancer	0.000441	0.00381	CbGeAlD
Pazopanib—EPHB6—endometrium—cervical cancer	0.000439	0.00379	CbGeAlD
Pazopanib—PDGFRA—decidua—cervical cancer	0.000438	0.00379	CbGeAlD
Pazopanib—Muscle spasms—Topotecan—cervical cancer	0.000438	0.0116	CcSEcCtD
Pazopanib—STK10—renal system—cervical cancer	0.000435	0.00375	CbGeAlD
Pazopanib—TAOK3—renal system—cervical cancer	0.000433	0.00374	CbGeAlD
Pazopanib—FLT4—female gonad—cervical cancer	0.00043	0.00372	CbGeAlD
Pazopanib—PDGFRA—renal system—cervical cancer	0.00043	0.00372	CbGeAlD
Pazopanib—FLT1—mammalian vulva—cervical cancer	0.000429	0.00371	CbGeAlD
Pazopanib—PIP4K2C—female gonad—cervical cancer	0.000428	0.0037	CbGeAlD
Pazopanib—PIP4K2C—vagina—cervical cancer	0.000425	0.00367	CbGeAlD
Pazopanib—FGFR1—female gonad—cervical cancer	0.000425	0.00367	CbGeAlD
Pazopanib—EPHB6—mammalian vulva—cervical cancer	0.000425	0.00367	CbGeAlD
Pazopanib—SH2B3—lymph node—cervical cancer	0.000424	0.00366	CbGeAlD
Pazopanib—FGFR1—vagina—cervical cancer	0.000422	0.00365	CbGeAlD
Pazopanib—Anaemia—Topotecan—cervical cancer	0.000421	0.0111	CcSEcCtD
Pazopanib—FGF1—female reproductive system—cervical cancer	0.00042	0.00363	CbGeAlD
Pazopanib—TAOK3—endometrium—cervical cancer	0.000419	0.00362	CbGeAlD
Pazopanib—KDR—epithelium—cervical cancer	0.000419	0.00361	CbGeAlD
Pazopanib—AURKC—lymph node—cervical cancer	0.000417	0.0036	CbGeAlD
Pazopanib—MAP2K5—uterine cervix—cervical cancer	0.000415	0.00358	CbGeAlD
Pazopanib—KDR—uterine cervix—cervical cancer	0.000415	0.00358	CbGeAlD
Pazopanib—UGT1A1—renal system—cervical cancer	0.000411	0.00355	CbGeAlD
Pazopanib—FLT1—uterus—cervical cancer	0.000409	0.00353	CbGeAlD
Pazopanib—Leukopenia—Topotecan—cervical cancer	0.000407	0.0108	CcSEcCtD
Pazopanib—STK10—mammalian vulva—cervical cancer	0.000407	0.00351	CbGeAlD
Pazopanib—MAP3K2—female gonad—cervical cancer	0.000406	0.00351	CbGeAlD
Pazopanib—TAOK3—mammalian vulva—cervical cancer	0.000405	0.0035	CbGeAlD
Pazopanib—CSF1R—uterine cervix—cervical cancer	0.000405	0.0035	CbGeAlD
Pazopanib—Cough—Topotecan—cervical cancer	0.000397	0.0105	CcSEcCtD
Pazopanib—FGFR2—female reproductive system—cervical cancer	0.000397	0.00343	CbGeAlD
Pazopanib—KDR—decidua—cervical cancer	0.000395	0.00341	CbGeAlD
Pazopanib—MAP2K5—decidua—cervical cancer	0.000395	0.00341	CbGeAlD
Pazopanib—KDR—renal system—cervical cancer	0.000388	0.00335	CbGeAlD
Pazopanib—Arthralgia—Topotecan—cervical cancer	0.000387	0.0102	CcSEcCtD
Pazopanib—Myalgia—Topotecan—cervical cancer	0.000387	0.0102	CcSEcCtD
Pazopanib—Chest pain—Topotecan—cervical cancer	0.000387	0.0102	CcSEcCtD
Pazopanib—STK10—uterus—cervical cancer	0.000387	0.00335	CbGeAlD
Pazopanib—CSF1R—decidua—cervical cancer	0.000386	0.00333	CbGeAlD
Pazopanib—TAOK3—uterus—cervical cancer	0.000386	0.00333	CbGeAlD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000385	0.0102	CcSEcCtD
Pazopanib—PDGFRA—uterus—cervical cancer	0.000383	0.00331	CbGeAlD
Pazopanib—FGF1—female gonad—cervical cancer	0.000382	0.0033	CbGeAlD
Pazopanib—PLK4—lymph node—cervical cancer	0.000381	0.00329	CbGeAlD
Pazopanib—LCK—female gonad—cervical cancer	0.00038	0.00328	CbGeAlD
Pazopanib—LCK—vagina—cervical cancer	0.000378	0.00326	CbGeAlD
Pazopanib—KDR—endometrium—cervical cancer	0.000375	0.00324	CbGeAlD
Pazopanib—MAP2K5—endometrium—cervical cancer	0.000375	0.00324	CbGeAlD
Pazopanib—KIT—epithelium—cervical cancer	0.000371	0.0032	CbGeAlD
Pazopanib—Infection—Topotecan—cervical cancer	0.000369	0.00976	CcSEcCtD
Pazopanib—FLT1—female reproductive system—cervical cancer	0.000368	0.00318	CbGeAlD
Pazopanib—KIT—uterine cervix—cervical cancer	0.000368	0.00318	CbGeAlD
Pazopanib—CSF1R—endometrium—cervical cancer	0.000366	0.00316	CbGeAlD
Pazopanib—Nervous system disorder—Topotecan—cervical cancer	0.000364	0.00963	CcSEcCtD
Pazopanib—Thrombocytopenia—Topotecan—cervical cancer	0.000364	0.00962	CcSEcCtD
Pazopanib—KDR—mammalian vulva—cervical cancer	0.000363	0.00314	CbGeAlD
Pazopanib—MAP2K5—mammalian vulva—cervical cancer	0.000363	0.00314	CbGeAlD
Pazopanib—PDGFRB—epithelium—cervical cancer	0.000362	0.00313	CbGeAlD
Pazopanib—FGFR2—female gonad—cervical cancer	0.000361	0.00312	CbGeAlD
Pazopanib—Skin disorder—Topotecan—cervical cancer	0.000361	0.00954	CcSEcCtD
Pazopanib—STK16—lymph node—cervical cancer	0.00036	0.00311	CbGeAlD
Pazopanib—PDGFRB—uterine cervix—cervical cancer	0.000359	0.0031	CbGeAlD
Pazopanib—Hyperhidrosis—Topotecan—cervical cancer	0.000359	0.0095	CcSEcCtD
Pazopanib—RIOK2—lymph node—cervical cancer	0.000355	0.00306	CbGeAlD
Pazopanib—CSF1R—mammalian vulva—cervical cancer	0.000354	0.00306	CbGeAlD
Pazopanib—Anorexia—Topotecan—cervical cancer	0.000354	0.00936	CcSEcCtD
Pazopanib—BMPR1B—lymph node—cervical cancer	0.000351	0.00303	CbGeAlD
Pazopanib—KIT—decidua—cervical cancer	0.00035	0.00303	CbGeAlD
Pazopanib—STK10—female reproductive system—cervical cancer	0.000348	0.00301	CbGeAlD
Pazopanib—TAOK3—female reproductive system—cervical cancer	0.000347	0.003	CbGeAlD
Pazopanib—KDR—uterus—cervical cancer	0.000346	0.00299	CbGeAlD
Pazopanib—PDGFRA—female reproductive system—cervical cancer	0.000345	0.00298	CbGeAlD
Pazopanib—KIT—renal system—cervical cancer	0.000344	0.00297	CbGeAlD
Pazopanib—PDGFRB—decidua—cervical cancer	0.000342	0.00296	CbGeAlD
Pazopanib—SLCO1B1—renal system—cervical cancer	0.000342	0.00295	CbGeAlD
Pazopanib—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000338	0.00895	CcSEcCtD
Pazopanib—CSF1R—uterus—cervical cancer	0.000338	0.00292	CbGeAlD
Pazopanib—PDGFRB—renal system—cervical cancer	0.000336	0.0029	CbGeAlD
Pazopanib—FLT1—female gonad—cervical cancer	0.000335	0.00289	CbGeAlD
Pazopanib—Paraesthesia—Topotecan—cervical cancer	0.000334	0.00882	CcSEcCtD
Pazopanib—FLT1—vagina—cervical cancer	0.000333	0.00287	CbGeAlD
Pazopanib—KIT—endometrium—cervical cancer	0.000333	0.00287	CbGeAlD
Pazopanib—Dyspnoea—Topotecan—cervical cancer	0.000331	0.00876	CcSEcCtD
Pazopanib—EPHB6—female gonad—cervical cancer	0.000331	0.00286	CbGeAlD
Pazopanib—EPHB6—vagina—cervical cancer	0.000329	0.00284	CbGeAlD
Pazopanib—Dyspepsia—Topotecan—cervical cancer	0.000327	0.00865	CcSEcCtD
Pazopanib—PDGFRB—endometrium—cervical cancer	0.000325	0.00281	CbGeAlD
Pazopanib—Decreased appetite—Topotecan—cervical cancer	0.000323	0.00854	CcSEcCtD
Pazopanib—KIT—mammalian vulva—cervical cancer	0.000322	0.00278	CbGeAlD
Pazopanib—Gastrointestinal disorder—Topotecan—cervical cancer	0.000321	0.00848	CcSEcCtD
Pazopanib—Fatigue—Topotecan—cervical cancer	0.00032	0.00847	CcSEcCtD
Pazopanib—STK36—lymph node—cervical cancer	0.000319	0.00275	CbGeAlD
Pazopanib—Pain—Topotecan—cervical cancer	0.000318	0.0084	CcSEcCtD
Pazopanib—STK10—female gonad—cervical cancer	0.000317	0.00274	CbGeAlD
Pazopanib—TAOK3—female gonad—cervical cancer	0.000316	0.00273	CbGeAlD
Pazopanib—STK10—vagina—cervical cancer	0.000315	0.00272	CbGeAlD
Pazopanib—PDGFRB—mammalian vulva—cervical cancer	0.000314	0.00271	CbGeAlD
Pazopanib—TAOK3—vagina—cervical cancer	0.000314	0.00271	CbGeAlD
Pazopanib—PI4KB—lymph node—cervical cancer	0.000314	0.00271	CbGeAlD
Pazopanib—PDGFRA—female gonad—cervical cancer	0.000314	0.00271	CbGeAlD
Pazopanib—PDGFRA—vagina—cervical cancer	0.000312	0.00269	CbGeAlD
Pazopanib—KDR—female reproductive system—cervical cancer	0.000311	0.00269	CbGeAlD
Pazopanib—MAP2K5—female reproductive system—cervical cancer	0.000311	0.00269	CbGeAlD
Pazopanib—LIMK2—lymph node—cervical cancer	0.000308	0.00266	CbGeAlD
Pazopanib—KIT—uterus—cervical cancer	0.000306	0.00265	CbGeAlD
Pazopanib—Gastrointestinal pain—Topotecan—cervical cancer	0.000304	0.00803	CcSEcCtD
Pazopanib—CSF1R—female reproductive system—cervical cancer	0.000303	0.00262	CbGeAlD
Pazopanib—PDGFRB—uterus—cervical cancer	0.000299	0.00259	CbGeAlD
Pazopanib—Abdominal pain—Topotecan—cervical cancer	0.000294	0.00777	CcSEcCtD
Pazopanib—KDR—female gonad—cervical cancer	0.000283	0.00244	CbGeAlD
Pazopanib—MAP2K5—female gonad—cervical cancer	0.000283	0.00244	CbGeAlD
Pazopanib—KDR—vagina—cervical cancer	0.000281	0.00243	CbGeAlD
Pazopanib—MAP2K5—vagina—cervical cancer	0.000281	0.00243	CbGeAlD
Pazopanib—FLT4—lymph node—cervical cancer	0.000277	0.00239	CbGeAlD
Pazopanib—CSF1R—female gonad—cervical cancer	0.000276	0.00238	CbGeAlD
Pazopanib—KIT—female reproductive system—cervical cancer	0.000276	0.00238	CbGeAlD
Pazopanib—PIP4K2C—lymph node—cervical cancer	0.000275	0.00238	CbGeAlD
Pazopanib—CSF1R—vagina—cervical cancer	0.000274	0.00237	CbGeAlD
Pazopanib—SLCO1B1—female reproductive system—cervical cancer	0.000274	0.00236	CbGeAlD
Pazopanib—FGFR1—lymph node—cervical cancer	0.000273	0.00236	CbGeAlD
Pazopanib—PDGFRB—female reproductive system—cervical cancer	0.000269	0.00232	CbGeAlD
Pazopanib—Asthenia—Topotecan—cervical cancer	0.000267	0.00705	CcSEcCtD
Pazopanib—Pruritus—Topotecan—cervical cancer	0.000263	0.00695	CcSEcCtD
Pazopanib—MAP3K2—lymph node—cervical cancer	0.000261	0.00225	CbGeAlD
Pazopanib—Diarrhoea—Topotecan—cervical cancer	0.000254	0.00672	CcSEcCtD
Pazopanib—KIT—female gonad—cervical cancer	0.000251	0.00217	CbGeAlD
Pazopanib—KIT—vagina—cervical cancer	0.000249	0.00215	CbGeAlD
Pazopanib—FGF1—lymph node—cervical cancer	0.000246	0.00212	CbGeAlD
Pazopanib—Dizziness—Topotecan—cervical cancer	0.000246	0.0065	CcSEcCtD
Pazopanib—PDGFRB—female gonad—cervical cancer	0.000245	0.00211	CbGeAlD
Pazopanib—LCK—lymph node—cervical cancer	0.000244	0.00211	CbGeAlD
Pazopanib—PDGFRB—vagina—cervical cancer	0.000243	0.0021	CbGeAlD
Pazopanib—Vomiting—Topotecan—cervical cancer	0.000236	0.00625	CcSEcCtD
Pazopanib—Rash—Topotecan—cervical cancer	0.000234	0.00619	CcSEcCtD
Pazopanib—Dermatitis—Topotecan—cervical cancer	0.000234	0.00619	CcSEcCtD
Pazopanib—Headache—Topotecan—cervical cancer	0.000233	0.00615	CcSEcCtD
Pazopanib—Nausea—Topotecan—cervical cancer	0.000221	0.00584	CcSEcCtD
Pazopanib—FLT1—lymph node—cervical cancer	0.000215	0.00186	CbGeAlD
Pazopanib—EPHB6—lymph node—cervical cancer	0.000213	0.00184	CbGeAlD
Pazopanib—STK10—lymph node—cervical cancer	0.000204	0.00176	CbGeAlD
Pazopanib—TAOK3—lymph node—cervical cancer	0.000203	0.00175	CbGeAlD
Pazopanib—ABCG2—uterine cervix—cervical cancer	0.000202	0.00174	CbGeAlD
Pazopanib—PDGFRA—lymph node—cervical cancer	0.000202	0.00174	CbGeAlD
Pazopanib—CYP2C8—renal system—cervical cancer	0.000194	0.00168	CbGeAlD
Pazopanib—ABCG2—decidua—cervical cancer	0.000192	0.00166	CbGeAlD
Pazopanib—CYP2C8—endometrium—cervical cancer	0.000188	0.00162	CbGeAlD
Pazopanib—ABCG2—endometrium—cervical cancer	0.000183	0.00158	CbGeAlD
Pazopanib—KDR—lymph node—cervical cancer	0.000182	0.00157	CbGeAlD
Pazopanib—MAP2K5—lymph node—cervical cancer	0.000182	0.00157	CbGeAlD
Pazopanib—CYP1A2—renal system—cervical cancer	0.000182	0.00157	CbGeAlD
Pazopanib—CSF1R—lymph node—cervical cancer	0.000177	0.00153	CbGeAlD
Pazopanib—ABCG2—mammalian vulva—cervical cancer	0.000177	0.00153	CbGeAlD
Pazopanib—ABCG2—uterus—cervical cancer	0.000168	0.00145	CbGeAlD
Pazopanib—KIT—lymph node—cervical cancer	0.000161	0.00139	CbGeAlD
Pazopanib—PDGFRB—lymph node—cervical cancer	0.000157	0.00136	CbGeAlD
Pazopanib—CYP2C8—female reproductive system—cervical cancer	0.000156	0.00134	CbGeAlD
Pazopanib—CYP2C8—vagina—cervical cancer	0.000141	0.00122	CbGeAlD
Pazopanib—ABCG2—female gonad—cervical cancer	0.000138	0.00119	CbGeAlD
Pazopanib—ABCG2—vagina—cervical cancer	0.000137	0.00118	CbGeAlD
Pazopanib—CYP3A4—renal system—cervical cancer	0.000132	0.00114	CbGeAlD
Pazopanib—CYP2D6—renal system—cervical cancer	0.000129	0.00112	CbGeAlD
Pazopanib—CYP3A4—female reproductive system—cervical cancer	0.000105	0.00091	CbGeAlD
Pazopanib—CYP2D6—female reproductive system—cervical cancer	0.000104	0.000896	CbGeAlD
Pazopanib—ABCB1—epithelium—cervical cancer	0.0001	0.000867	CbGeAlD
Pazopanib—ABCB1—uterine cervix—cervical cancer	9.95e-05	0.00086	CbGeAlD
Pazopanib—ABCB1—decidua—cervical cancer	9.48e-05	0.000819	CbGeAlD
Pazopanib—CYP2D6—female gonad—cervical cancer	9.43e-05	0.000815	CbGeAlD
Pazopanib—ABCB1—renal system—cervical cancer	9.31e-05	0.000804	CbGeAlD
Pazopanib—ABCB1—endometrium—cervical cancer	9e-05	0.000778	CbGeAlD
Pazopanib—ABCG2—lymph node—cervical cancer	8.85e-05	0.000764	CbGeAlD
Pazopanib—ABCB1—mammalian vulva—cervical cancer	8.71e-05	0.000752	CbGeAlD
Pazopanib—ABCB1—uterus—cervical cancer	8.3e-05	0.000717	CbGeAlD
Pazopanib—ABCB1—female reproductive system—cervical cancer	7.46e-05	0.000644	CbGeAlD
Pazopanib—ABCB1—female gonad—cervical cancer	6.79e-05	0.000586	CbGeAlD
Pazopanib—ABCB1—vagina—cervical cancer	6.75e-05	0.000583	CbGeAlD
Pazopanib—ABCB1—lymph node—cervical cancer	4.36e-05	0.000377	CbGeAlD
Pazopanib—KIT—Disease—NOTCH1—cervical cancer	1.08e-05	0.000104	CbGpPWpGaD
Pazopanib—FGF1—Immune System—MTOR—cervical cancer	1.08e-05	0.000103	CbGpPWpGaD
Pazopanib—FGF1—Immune System—CD4—cervical cancer	1.08e-05	0.000103	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—EGFR—cervical cancer	1.08e-05	0.000103	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MTHFR—cervical cancer	1.07e-05	0.000103	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—TERT—cervical cancer	1.07e-05	0.000103	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CA9—cervical cancer	1.07e-05	0.000102	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—FGFR3—cervical cancer	1.07e-05	0.000102	CbGpPWpGaD
Pazopanib—KIT—Immune System—CASP8—cervical cancer	1.07e-05	0.000102	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—FGFR3—cervical cancer	1.06e-05	0.000102	CbGpPWpGaD
Pazopanib—FGFR3—Disease—CTNNB1—cervical cancer	1.06e-05	0.000102	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—EGFR—cervical cancer	1.06e-05	0.000101	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD8A—cervical cancer	1.04e-05	0.0001	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NOTCH2—cervical cancer	1.04e-05	9.99e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—FGFR3—cervical cancer	1.04e-05	9.98e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—FGFR3—cervical cancer	1.04e-05	9.96e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—EGFR—cervical cancer	1.04e-05	9.92e-05	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—EGFR—cervical cancer	1.04e-05	9.91e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—MTOR—cervical cancer	1.03e-05	9.88e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—CD4—cervical cancer	1.03e-05	9.86e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—NOTCH1—cervical cancer	1.03e-05	9.83e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—NOTCH1—cervical cancer	1.02e-05	9.8e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NOTCH2—cervical cancer	1.02e-05	9.78e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HES1—cervical cancer	1.02e-05	9.78e-05	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—EGFR—cervical cancer	1.02e-05	9.73e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CASP8—cervical cancer	1.01e-05	9.7e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—CASP3—cervical cancer	1.01e-05	9.69e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CASP8—cervical cancer	1.01e-05	9.67e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—EGFR—cervical cancer	1.01e-05	9.62e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—STAT3—cervical cancer	1.01e-05	9.62e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HES1—cervical cancer	1e-05	9.61e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—NOTCH1—cervical cancer	1e-05	9.6e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—EGFR—cervical cancer	1e-05	9.6e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—EGFR—cervical cancer	1e-05	9.58e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—MTOR—cervical cancer	9.98e-06	9.55e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—CD4—cervical cancer	9.96e-06	9.53e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—FGFR3—cervical cancer	9.93e-06	9.5e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—MTOR—cervical cancer	9.91e-06	9.48e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—CD4—cervical cancer	9.89e-06	9.47e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—FGFR3—cervical cancer	9.83e-06	9.41e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—HES1—cervical cancer	9.81e-06	9.39e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—NOTCH1—cervical cancer	9.78e-06	9.35e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—CTNNB1—cervical cancer	9.76e-06	9.34e-05	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—EGFR—cervical cancer	9.65e-06	9.24e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—EGFR—cervical cancer	9.63e-06	9.21e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—CTNNB1—cervical cancer	9.58e-06	9.17e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HES1—cervical cancer	9.53e-06	9.12e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—TP53—cervical cancer	9.52e-06	9.1e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HES1—cervical cancer	9.5e-06	9.09e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—NOTCH1—cervical cancer	9.33e-06	8.92e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CA9—cervical cancer	9.32e-06	8.92e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—STAT3—cervical cancer	9.28e-06	8.88e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—NOTCH1—cervical cancer	9.23e-06	8.83e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	9.2e-06	8.8e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—CTNNB1—cervical cancer	9.15e-06	8.76e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—EGFR—cervical cancer	9.13e-06	8.74e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CASP8—cervical cancer	9.11e-06	8.71e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—EGFR—cervical cancer	9.03e-06	8.65e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TERT—cervical cancer	8.96e-06	8.57e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—MTOR—cervical cancer	8.94e-06	8.56e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—CD4—cervical cancer	8.93e-06	8.54e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—CASP8—cervical cancer	8.92e-06	8.53e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—CTNNB1—cervical cancer	8.85e-06	8.47e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—EGFR—cervical cancer	8.85e-06	8.46e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TERT—cervical cancer	8.8e-06	8.42e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—MTOR—cervical cancer	8.78e-06	8.41e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CA9—cervical cancer	8.78e-06	8.4e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—CD4—cervical cancer	8.77e-06	8.39e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—TP53—cervical cancer	8.7e-06	8.33e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—EGFR—cervical cancer	8.68e-06	8.3e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MTHFR—cervical cancer	8.62e-06	8.25e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—TERT—cervical cancer	8.6e-06	8.23e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HES1—cervical cancer	8.56e-06	8.19e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—FGFR3—cervical cancer	8.55e-06	8.18e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—STAT3—cervical cancer	8.51e-06	8.14e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—EGFR—cervical cancer	8.49e-06	8.13e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—EGFR—cervical cancer	8.43e-06	8.07e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MTOR—cervical cancer	8.41e-06	8.05e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HES1—cervical cancer	8.38e-06	8.02e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NOTCH2—cervical cancer	8.38e-06	8.02e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—STAT3—cervical cancer	8.35e-06	7.99e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TERT—cervical cancer	8.35e-06	7.99e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—MTOR—cervical cancer	8.34e-06	7.98e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TERT—cervical cancer	8.33e-06	7.97e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CD4—cervical cancer	8.32e-06	7.96e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—MTOR—cervical cancer	8.32e-06	7.96e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CD4—cervical cancer	8.3e-06	7.94e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—MTOR—cervical cancer	8.26e-06	7.9e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—TP53—cervical cancer	8.25e-06	7.89e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—MTHFR—cervical cancer	8.24e-06	7.89e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—CD4—cervical cancer	8.24e-06	7.89e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—FGFR3—cervical cancer	8.22e-06	7.87e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—MTOR—cervical cancer	8.11e-06	7.76e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—CD4—cervical cancer	8.1e-06	7.75e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—FGFR3—cervical cancer	8.07e-06	7.73e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—CTNNB1—cervical cancer	7.93e-06	7.59e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—FGFR3—cervical cancer	7.89e-06	7.55e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—CTNNB1—cervical cancer	7.79e-06	7.45e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CASP3—cervical cancer	7.73e-06	7.4e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—EGFR—cervical cancer	7.73e-06	7.4e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	7.72e-06	7.39e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NOTCH1—cervical cancer	7.72e-06	7.39e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—STAT3—cervical cancer	7.71e-06	7.38e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MTOR—cervical cancer	7.7e-06	7.37e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—CD4—cervical cancer	7.68e-06	7.35e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MTOR—cervical cancer	7.68e-06	7.35e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—CD4—cervical cancer	7.66e-06	7.33e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—FGFR3—cervical cancer	7.66e-06	7.33e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—FGFR3—cervical cancer	7.64e-06	7.31e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—EGFR—cervical cancer	7.59e-06	7.26e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NOTCH1—cervical cancer	7.58e-06	7.25e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—MTHFR—cervical cancer	7.55e-06	7.23e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MTOR—cervical cancer	7.52e-06	7.19e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TERT—cervical cancer	7.5e-06	7.18e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—MTOR—cervical cancer	7.49e-06	7.17e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CD4—cervical cancer	7.48e-06	7.16e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—CTNNB1—cervical cancer	7.45e-06	7.13e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CA9—cervical cancer	7.44e-06	7.12e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—NOTCH1—cervical cancer	7.41e-06	7.09e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CTNNB1—cervical cancer	7.39e-06	7.07e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CTNNB1—cervical cancer	7.37e-06	7.05e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TERT—cervical cancer	7.35e-06	7.03e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—MTOR—cervical cancer	7.33e-06	7.02e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MTOR—cervical cancer	7.33e-06	7.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—CTNNB1—cervical cancer	7.32e-06	7.01e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—CD4—cervical cancer	7.32e-06	7.01e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CASP8—cervical cancer	7.31e-06	6.99e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—EGFR—cervical cancer	7.25e-06	6.94e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NOTCH1—cervical cancer	7.19e-06	6.88e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—CTNNB1—cervical cancer	7.19e-06	6.88e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NOTCH1—cervical cancer	7.18e-06	6.87e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—EGFR—cervical cancer	7.01e-06	6.71e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—MTHFR—cervical cancer	7e-06	6.69e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MTOR—cervical cancer	6.99e-06	6.69e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—EGFR—cervical cancer	6.96e-06	6.66e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MTOR—cervical cancer	6.92e-06	6.62e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CASP3—cervical cancer	6.91e-06	6.62e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—STAT3—cervical cancer	6.91e-06	6.61e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—CD4—cervical cancer	6.9e-06	6.61e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—FGFR3—cervical cancer	6.89e-06	6.59e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HES1—cervical cancer	6.87e-06	6.58e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—CTNNB1—cervical cancer	6.82e-06	6.53e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—CTNNB1—cervical cancer	6.81e-06	6.51e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—STAT3—cervical cancer	6.79e-06	6.5e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TP53—cervical cancer	6.76e-06	6.47e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—FGFR3—cervical cancer	6.74e-06	6.45e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CASP3—cervical cancer	6.74e-06	6.45e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CTNNB1—cervical cancer	6.66e-06	6.38e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CTNNB1—cervical cancer	6.64e-06	6.36e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—CTNNB1—cervical cancer	6.5e-06	6.22e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—STAT3—cervical cancer	6.5e-06	6.22e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CTNNB1—cervical cancer	6.49e-06	6.21e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TP53—cervical cancer	6.49e-06	6.21e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NOTCH1—cervical cancer	6.46e-06	6.19e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—STAT3—cervical cancer	6.44e-06	6.17e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CASP3—cervical cancer	6.43e-06	6.15e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—STAT3—cervical cancer	6.43e-06	6.15e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—STAT3—cervical cancer	6.38e-06	6.11e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NOTCH1—cervical cancer	6.33e-06	6.06e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—EGFR—cervical cancer	6.28e-06	6.01e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—STAT3—cervical cancer	6.27e-06	6e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CTNNB1—cervical cancer	6.2e-06	5.93e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—EGFR—cervical cancer	6.17e-06	5.9e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—CTNNB1—cervical cancer	6.13e-06	5.87e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TERT—cervical cancer	6.02e-06	5.76e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—MTOR—cervical cancer	6.01e-06	5.75e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD4—cervical cancer	6e-06	5.74e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—STAT3—cervical cancer	5.95e-06	5.69e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—STAT3—cervical cancer	5.93e-06	5.68e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—EGFR—cervical cancer	5.91e-06	5.65e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—EGFR—cervical cancer	5.86e-06	5.6e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—EGFR—cervical cancer	5.84e-06	5.59e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—STAT3—cervical cancer	5.81e-06	5.56e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—EGFR—cervical cancer	5.8e-06	5.55e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—STAT3—cervical cancer	5.79e-06	5.54e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MTOR—cervical cancer	5.78e-06	5.53e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CA9—cervical cancer	5.74e-06	5.49e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—EGFR—cervical cancer	5.7e-06	5.45e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MTOR—cervical cancer	5.68e-06	5.43e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—STAT3—cervical cancer	5.67e-06	5.42e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—STAT3—cervical cancer	5.66e-06	5.42e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MTOR—cervical cancer	5.55e-06	5.31e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CD4—cervical cancer	5.54e-06	5.3e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—FGFR3—cervical cancer	5.53e-06	5.29e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—EGFR—cervical cancer	5.41e-06	5.17e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—STAT3—cervical cancer	5.4e-06	5.17e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—EGFR—cervical cancer	5.39e-06	5.16e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MTOR—cervical cancer	5.39e-06	5.16e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MTOR—cervical cancer	5.38e-06	5.14e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—STAT3—cervical cancer	5.35e-06	5.12e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CTNNB1—cervical cancer	5.33e-06	5.1e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CASP3—cervical cancer	5.32e-06	5.09e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—EGFR—cervical cancer	5.28e-06	5.05e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—EGFR—cervical cancer	5.26e-06	5.04e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CASP3—cervical cancer	5.22e-06	5e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NOTCH1—cervical cancer	5.19e-06	4.96e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—EGFR—cervical cancer	5.15e-06	4.93e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—EGFR—cervical cancer	5.15e-06	4.92e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CTNNB1—cervical cancer	5.13e-06	4.91e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CTNNB1—cervical cancer	5.04e-06	4.82e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—cervical cancer	4.96e-06	4.75e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CASP3—cervical cancer	4.96e-06	4.74e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CASP3—cervical cancer	4.95e-06	4.73e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CTNNB1—cervical cancer	4.92e-06	4.71e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EGFR—cervical cancer	4.91e-06	4.7e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—EGFR—cervical cancer	4.86e-06	4.65e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MTOR—cervical cancer	4.84e-06	4.63e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CTNNB1—cervical cancer	4.78e-06	4.57e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CTNNB1—cervical cancer	4.77e-06	4.56e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MTOR—cervical cancer	4.74e-06	4.54e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—STAT3—cervical cancer	4.65e-06	4.45e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—STAT3—cervical cancer	4.47e-06	4.28e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CASP3—cervical cancer	4.46e-06	4.26e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—cervical cancer	4.43e-06	4.24e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—STAT3—cervical cancer	4.39e-06	4.2e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CASP3—cervical cancer	4.36e-06	4.17e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—MTHFR—cervical cancer	4.34e-06	4.15e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—cervical cancer	4.32e-06	4.13e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CTNNB1—cervical cancer	4.29e-06	4.11e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—STAT3—cervical cancer	4.29e-06	4.1e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—cervical cancer	4.22e-06	4.04e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CTNNB1—cervical cancer	4.2e-06	4.02e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—STAT3—cervical cancer	4.17e-06	3.99e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—STAT3—cervical cancer	4.16e-06	3.98e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—cervical cancer	4.12e-06	3.94e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—cervical cancer	4.06e-06	3.89e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—cervical cancer	3.99e-06	3.82e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—cervical cancer	3.9e-06	3.73e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MTOR—cervical cancer	3.89e-06	3.72e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—cervical cancer	3.79e-06	3.62e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—MTHFR—cervical cancer	3.78e-06	3.62e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—cervical cancer	3.78e-06	3.61e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—STAT3—cervical cancer	3.74e-06	3.58e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—STAT3—cervical cancer	3.66e-06	3.51e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP3—cervical cancer	3.58e-06	3.42e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—MTHFR—cervical cancer	3.56e-06	3.41e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CTNNB1—cervical cancer	3.45e-06	3.3e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—cervical cancer	3.41e-06	3.26e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—cervical cancer	3.4e-06	3.26e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—cervical cancer	3.35e-06	3.21e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—cervical cancer	3.33e-06	3.19e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—cervical cancer	3.18e-06	3.04e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—cervical cancer	3.17e-06	3.03e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—MTHFR—cervical cancer	3.02e-06	2.89e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—STAT3—cervical cancer	3e-06	2.87e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—cervical cancer	2.86e-06	2.73e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—cervical cancer	2.8e-06	2.68e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—cervical cancer	2.73e-06	2.61e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MTHFR—cervical cancer	2.33e-06	2.23e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—cervical cancer	2.29e-06	2.19e-05	CbGpPWpGaD
